GlassScriptPhysician profile
Jeffrey L Kim
NPI 1275506560
$6,559.77
in general payments reported to CMS, 2019-2025
27 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $41.52 · 2021: $515 · 2022: $864 · 2023: $1,545 · 2024: $1,288 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,339 · Education: $94.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,339.40 |
| Education | $94.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,310.97 | 2021-2025 | Gi Genius, Interstim |
| Abbvie INC. | $1,227.08 | 2019-2025 | |
| Janssen Biotech, INC. | $647.00 | 2023-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $574.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $377.99 | 2022-2025 | Dupixent |
| Pfizer INC. | $369.33 | 2019-2025 | |
| Genzyme Corporation | $172.42 | 2023-2025 | |
| Ardelyx, INC. | $162.64 | 2023-2024 | Ibsrela |
| Celgene Corporation | $148.46 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $147.56 | 2024-2025 | Iqirvo, Bylvay |
| Janssen Scientific Affairs, LLC | $146.91 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $141.80 | 2023-2025 | Ocaliva |
| Regeneron Pharmaceuticals, INC. | $138.15 | 2023 | Dupixent |
| Covidien LP | $135.27 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.12 | 2023 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $126.79 | 2023 | Gimoti |
| Gilead Sciences, INC. | $125.11 | 2025 | |
| Genentech, INC. | $100.79 | 2019 | |
| Emd Serono, INC. | $88.48 | 2019 | |
| Lilly USA, LLC | $73.10 | 2024-2025 | Omvoh, Zepbound |
| Romark Laboratories, Lc | $72.49 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $63.84 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $21.08 | 2025 | Suflave, Sutab |
| Novo Nordisk INC | $17.85 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $14.14 | 2025 | Zenpep |
| Avion Pharmaceuticals | $12.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.